https://www.futuremedicine.com/doi/10.2217/bmm-2020-0683
Biomarkers in Medicine
Vol. 15, No. 10Special Report
Open Access
Screening for regenerative therapy responders in heart failure
Satsuki Yamada, Ryounghoon Jeon, Armin Garmany, Atta Behfar & Andre Terzic
Published Online: 25 Jun 2021
https://doi.org/10.2217/bmm-2020-0683
Abstract
Risk of outcome variability challenges therapeutic innovation. Selection of the most suitable candidates is predicated on reliable response indicators. Especially for emergent regenerative biotherapies, determinants separating success from failure in achieving disease rescue remain largely unknown. Accordingly, (pre)clinical development programs have placed increased emphasis on the multi-dimensional decoding of repair capacity and disease resolution, attributes defining responsiveness. To attain regenerative goals for each individual, phenotype-based patient selection is poised for an upgrade guided by new insights into disease biology, translated into refined surveillance of response regulators and deep learning-amplified clinical decision support.
https://www.futuremedicine.com/doi/10.2217/bmm-2020-0683...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.045(3.50%) |
Mkt cap ! $1.518B | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.35 | $1.30 | $2.885M | 2.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 7070 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |